Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDD biomarker-guided antidepressant response study
ACTRN12608000476336Phase 4Recruiting
- Sponsor
- Brain Resource
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of escitalopram, sertraline and venlafaxine in major depressive disorder (MDD) (4 arms), sponsored by Brain Resource. Primary endpoint: Prediction of acute antidepressant treatment response using composite multimodal markers. Started Jul 2008; status: recruiting.
02
Drugs
escitalopramsertralinevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12608000476336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000476336.